RT Journal Article
SR Electronic
T1 Circulating myeloid-derived suppressor cells and regulatory T cells as immunological biomarkers in refractory/relapsed diffuse large B-cell lymphoma: translational results from the R2-GDP-GOTEL trial
JF Journal for ImmunoTherapy of Cancer
JO J Immunother Cancer
FD BMJ Publishing Group Ltd
SP e002323
DO 10.1136/jitc-2020-002323
VO 9
IS 6
A1 Jiménez-Cortegana, Carlos
A1 Palazón-Carrión, Natalia
A1 Martin Garcia-Sancho, Alejandro
A1 Nogales-Fernandez, Esteban
A1 Carnicero-González, Fernando
A1 Ríos-Herranz, Eduardo
A1 de la Cruz-Vicente, Fatima
A1 Rodríguez-García, Guillermo
A1 Fernández-Álvarez, Rubén
A1 Rueda Dominguez, Antonio
A1 Casanova-Espinosa, Maria
A1 Martínez-Banaclocha, Natividad
A1 Gumà-Padrò, Josep
A1 Gómez-Codina, José
A1 Labrador, Jorge
A1 Salar-Silvestre, Antonio
A1 Rodriguez-Abreu, Delvys
A1 Galvez-Carvajal, Laura
A1 Provencio, Mariano
A1 Sánchez-Beato, Margarita
A1 Guirado-Risueño, María
A1 Espejo-García, Pablo
A1 Lejeune, Marylene
A1 Álvaro, Tomás
A1 Sánchez-Margalet, Victor
A1 de la Cruz-Merino, Luis
A1 
YR 2021
UL http://jitc.bmj.com/content/9/6/e002323.abstract
AB Background The search for immunological markers with ability of predicting clinical outcome is a priority in lymphomas, and in cancer in general. It is well known that some immunomodulatory cells, such as myeloid derived suppressor cells (MDSCs) or regulatory T cells (Tregs), are recruited by tumors, jeopardizing antitumor immunosurveillance. In this work, we have studied blood levels of these immunosuppressive cells in patients with relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL), prior to and along the course of the experimental rituximab, gemcitabine, dexamethasone, and cisplatin (R2-GDP) schedule, as a translational substudy of the R2-GDP-GOTEL trial (EudraCT Number: 2014-001620-29), which included lenalidomide as an immunomodulator.Methods Blood samples were taken before treatment, at cycle 3 and end of induction. Samples were analyzed by flow cytometry. Non-parametric tests were used. Mann-Whitney U test was used to compare basal cells distributions, and Wilcoxon test was considered to compare cells distribution at different times. Spearman test was performed to measure the degree of association between cell populations.Results In this study, MDSC and Treg circulating concentration was found increased in all patients compared with a healthy control group and decreased after treatment only in patients with longest overall survival (>24 months), reaching the levels of the healthy group. Likewise, the number of inhibited T lymphocytes expressing Programmed Death-1 (PD-1) were increased in peripheral blood from patients and decreased on the treatment, whereas activated T lymphocytes increased after therapy in those with better overall survival.Conclusions In conclusion, blood concentration of MDSCs and Treg cells may be good prognostic markers for overall survival after 2 years in R/R DLBCL. These results point to a possible role of these elements in the immunosuppression of these patients, as assessed by the circulating activated and inhibited T lymphocytes, and therefore, they may be considered as therapeutic targets in DLBCL.Data are available on reasonable request. Anonymised data are available on reasonable request.